Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE VC PLAIN versus SYPRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE VC PLAIN versus SYPRINE.
PROMETHAZINE VC PLAIN vs SYPRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative with antihistaminic (H1 receptor antagonist), sedative, antiemetic, and anticholinergic effects. Phenylephrine is a sympathomimetic amine acting primarily on alpha-1 adrenergic receptors, causing vasoconstriction.
Syprine (trientine hydrochloride) is a chelating agent that forms stable complexes with copper, thereby increasing urinary excretion of copper and reducing pathological copper accumulation in tissues.
Adults: 1 tablet (promethazine 6.25 mg, phenylephrine 10 mg) orally every 4-6 hours as needed, not to exceed 4 tablets in 24 hours.
250 mg to 500 mg orally 4 times daily, maximum 2000 mg daily.
None Documented
None Documented
Terminal elimination half-life is approximately 9–16 hours (mean ~12 hours) in adults; may be prolonged in hepatic impairment or elderly patients.
Approximately 48 hours in healthy subjects, reflecting prolonged accumulation with regular dosing, requiring careful monitoring for toxicity.
Primarily renal as inactive metabolites; approximately 70-80% excreted in urine, with about 20-30% in feces via biliary secretion. Less than 1% excreted unchanged.
Primarily renal (approximately 50% unchanged within 24 hours after oral administration); biliary/fecal elimination accounts for a minor fraction (less than 10%).
Category A/B
Category C
Antihistamine / Antiemetic
Antihistamine